Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies into Care for Patients with Relapsed/Refractory Multiple Myeloma

This educational activity is presented in collaboration with Rush University Medical Center and Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Pfizer, Inc.

RELEASE DATE

March 14, 2024

Expiration Date

March 14, 2025

ACTIVITY OVERVIEW

As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, patient and clinical factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administration of bispecific antibodies for R/R MM. The content emphasizes the crucial role of the team in improving the timing and quality of treatment as well as facilitating equitable access. This education tailors learning to your needs, providing an ongoing reference tool to enhance care in this complex landscape. 

TARGET AUDIENCE

This activity is intended for pharmacists, hematologists/oncologists, nurses, and other members of the multidisciplinary team.

Learning Objectives

Upon completion of this activity, pharmacists will be able to:

• Compare and contrast available bispecific antibodies for patients with heavily pretreated MM
• Optimally select and sequence therapies in heavily treated patients with R/R MM considerate of patient- and disease-related factors
• Discuss strategies to monitor and mitigate adverse events associated with bispecific antibodies for R/R MM
• Apply tactics to improve care coordination, access to care and SDM in diverse patients with R/R MM

ACTIVITY PURPOSE

Multiple myeloma (MM) is the second most common type of hematologic malignancy worldwide, with approximately 35,000 people receiving this diagnosis in 2023 in the United States. (ACS, 2023) Despite recent advances in treatment, MM is still considered an incurable malignancy; even with aggressive first-line therapy, most patients will relapse, and the 5-year overall survival is only 58%. (ACS, 2023) Continued research in MM has provided new treatment options, both for patients with newly diagnosed and with relapsed or refractory (R/R) disease.

The pursuit for tolerable and effective treatments in the R/R setting, especially for heavily treated patient populations, has resulted in novel targets and therapies. These include approaches to targeting B-cell maturation antigen (BCMA) as well as a novel target in MM, G protein-coupled receptor, family C, group 5, member D (GPRC5D).

Although for patients with MM this is a terrific time with novel therapies available and offering hope for treatment, these developments may pose challenges for clinicians treating MM. There are now three different bispecific antibodies with different dosing and administration and the potential for unique adverse events. As such, the multidisciplinary team requires an understanding of these agents, potential adverse events, and management strategies.

FACULTY

Beth Faiman PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland, OH

Rebecca LaRue, PharmD, BCOP
Clinical Pharmacy Specialist Hematology/Oncology/Cellular Therapy
Team Lead Hematology/Oncology Pharmacy
Rush University Medical Center
Chicago, IL

Surbhi Sidana, MD
Assistant Professor of Medicine
Director, Myeloma Cellular Immunotherapy & Myeloma Disease Focused Group, Division of BMT & Cell Therapy
Stanford University
Stanford, CA

FINANCIAL DISCLOSURE

It is the policy of Rush University Medical Center and the Office of Interprofessional Continuing Education (ICPE) to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE.  All individuals in control of educational content must disclose all financial relationships with ineligible companies in the past 24 months.  An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All conflicts of interest, including potential ones, for individuals in control of educational content are mitigated prior to the planning, implementation, or evaluation of the continuing education activity.

The IPCE identifies the presence or absence of relevant financial relationships for all individuals in control of content including but not limited to planning committee members, course directors, invited presenters/authors, and staff through a standardized disclosure form.  If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.

The following financial relationships have been provided:
Beth Faiman PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Consulting Agreements: Amgen, BMS, Janssen, Karyopharm, Pfizer, Sanofi

Rebecca LaRue, PharmD, BCOP
No financial relationships to disclose

Surbhi Sidana, MD
Sources of Funding for Research: AbbVie, Allogene Therapeutics, Bristol Myers Squibb, Janssen, Magenta Therapeutics, Novartis
Consulting Agreements: AbbVie, Bristol Myers Squibb, Janssen, Kite Pharma, Legend Biotech, Magenta Therapeutics, Novartis, Oncopeptides, Regeneron, Sanofi, Takeda

Off-label statement      
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices.  Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

Staff and Reviewer Disclosures
Rush University Medical Center and the Office of Interprofessional Continuing Education staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACCREDITATION STATEMENTS

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this application-based Internet Enduring Material for a maximum of 1.0 contact hour(s) for pharmacists. ACPE Universal Activity Number: JA0000275-0000-24-077-H01-P.

Method of Participation

This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Partial credit may not be awarded for CPE; participation in the complete activity is required to receive credit.

For questions, contact Katie Hacias at khacias@achlcme.org.

Agenda

Content is displayed in these sections:

• Bispecific Antibodies for R/R MM
• Potential Toxicities with Bispecific Antibodies for R/R MM
• Ensuring Racially and Ethnically Diverse Patients with R/R MM Receive New Therapies
• Improving Shared Decision-Making and Coordination of Care

Disclaimer

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Hardware/Software Requirements

Please ensure the computer system you plan to use meets the following minimum requirements:

• Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
• Compatible with Windows PC and MAC (256 MB of RAM or higher)
• Activity is best viewed on Internet Explorer 10.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
• Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
• Adobe Reader to print certificate. Click here to download Adobe Reader for free.
• Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
• Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker